Back to Clinical Trials
Phase 4Recruiting

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Sponsored by University of Illinois at Chicago

About this study

In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.

1.0 Background While atrial fibrillation (AF) is the most common sustained cardiac arrhythmia requiring therapy, it is also associated with increased risk of stroke, heart failure, myocardial infarction, dementia, and death. The number of Americans affected with AF is expected to surge to nearly 16 million by the year 2050. The AF epidemic may in part be related to the aging of the population and increasing prevalence of recently identified risk factors including obesity, metabolic syndrome, obstructive sleep apnea, and inflammation. Furthermore, there is increasing support for the idea that both common and rare genetic variants also increase susceptibility to AF which can clinically manifest in the presence of acquired risk factors. While clinical risk factors for AF are established, the…

Where this study is enrolling (4)

Who can participate

Inclusion criteria

  • ✓≥ 18 years of age
  • ✓History of typical or early-onset symptomatic (≥2 episodes/month) paroxysmal/persistent AF
  • ✓ECG that was recorded within 1 month of randomization showing AF
  • ✓Eligible for both Flecainide(Class I) and Sotalol (Class III) AAD
  • ✓Able to give informed consent

Exclusion criteria

  • ✕Permanent AF or isolated atrial flutter
  • ✕Cardiac or thoracic surgery within the previous 6 months
  • ✕Previous use of amiodarone other than short-term use (e.g. for an acute arrhythmia in hospital)
  • ✕Medical condition that is likely to be fatal in less than one year
  • ✕A history of prior AF ablation
  • ✕Have already been tried on 2 or more AADs in the past for AF
  • ✕Creatinine clearance \<40 ml/min
  • ✕Left ventricular ejection fraction \< 50%
  • ✕Contra-indication to a Class I AAD e.g., structural heart disease, or history of MI
  • ✕Contra-indication to a Class III AAD, e.g., congenital or acquired long QT syndrome with QTc\>480 ms in females and \>460 ms in males at baseline
  • ✕A reversible cause of AF (e.g., hyperthyroidism)
  • ✕Females who are pregnant or nursing
  • ✕History of severe AV node dysfunction unless an electronic pacemaker is present
  • ✕First- or second-degree relative has already participated in the study
  • ✕Unable to adhere to study procedures that are strictly for research purposes

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.